Velaglucerasa Alfa

Velaglucerasa Alfa Uses, Dosage, Side Effects, Food Interaction and all others data.

Velaglucerasa Alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, Velaglucerasa Alfa has also been investigated for use in Type 3 Gaucher disease.

Table Of contents

• Velaglucerasa Alfa
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Velaglucerasa Alfa
Generic	Velaglucerase alfa
Velaglucerase alfa Other Names	GA-GCB, Velaglucerasa alfa, Velaglucerase alfa
Type
Formula	C2532H3850N672O711S16
Weight	63000.0 Da (approximate)
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Velaglucerasa Alfa is an enzyme replacement therapy used for the long-term treatment of for pediatric and adult patients with type 1 Gaucher disease.

Velaglucerasa Alfa is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with type 1 Gaucher disease.

Velaglucerasa Alfa is also used to associated treatment for these conditions: Gaucher Disease, Type 1

How Velaglucerasa Alfa works

Velaglucerasa Alfa catalyzes the hydrolysis of glucocerebroside, reducing the amount of accumulated glucocerebroside.

Food Interaction

No interactions found.

Volume of Distribution

The mean volume of distribution at steady state ranges from 82 to 108 mL/kg (8.2% to 10.8% of body weight).

Half Life

11-12 minutes.

Clearance

Mean clearance ranges from 6.72 to 7.56 mL/min/kg.

Innovators Monograph

You find simplified version here Velaglucerasa Alfa